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SUMMARY 
So far, some prospective metal-based anti-malarial drugs have been developed. The mechanochemical 
synthesis and characterization of Zn (II) complex with amodiaquine and its anti-malarial efficacy on Plasmodium 
berghei-infected mice and safety evaluation were described in this study. 
Solvent-free mechanochemical synthesis and characterization of Zn (II) complex with amodiaquine as well 
as its anti-malarial efficacy on NK-65 Plasmodium berghei-infected mice and safety were evaluated.  
Derivatization of amodiaquine with zinc (II) ion enhanced the activity of the drug through significant  
(p < 0.05) enhancement of parasitemia suppression in established malaria infection in comparison with the 
controls, while its capacity to clear malaria parasite was similar to that of chloroquine. A significant reduction in 
the liver, kidney and small intestinal activities of alkaline phosphatase, lactate dehydrogenase and alanine and 
aspartate aminotransferases was observed, while their levels increased significantly in the plasma. Levels of PCV, 
Hb, RBC and lymphocytes were significantly reduced (p < 0.05), and significant elevation (p < 0.05) in WBC and 
neutrophil concentrations across all the treatment groups when compared with control was observed.  
The result indicates that coordination of zinc (II) to amodiaquine by mechanical induction improved its 
anti-malarial activity, while the alterations in the investigated biochemical parameters suggest functional and 
structural toxicity. Thus, Zn (II) complex with amodiaquine may not be completely safe for prolonged and 
repeated use as an oral anti-malarial remedy. 
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INTRODUCTION 
Malaria, a parasitic disease which occurs mainly 
in tropical zones of the world, has contributed greatly to 
health burden of the global population. According to the 
latest estimate, malaria affects more than 2 million 
people annually and causes about 627,000 deaths (1).  In 
Africa, the majority of deaths occur among children, 
where estimate has it that the death of a child resulting 
from malaria occurs every minute (1). All year round, 
cases of transmission occur in the southern part of 
Nigeria; it is, however, more seasonal in the North (2). 
Plasmodium parasite causes malaria and it is trans-
mitted to the human through the bites of infected Ano-
pheles mosquito which bites mainly between dusk and 
dawn. Plasmodium falciparum, Plasmodium vivax, 
Plasmodium malariae and Plasmodium ovale are the four 
species of plasmodium that cause human malaria (3). P. 
falciparum most frequently causes the infection and is 
responsible for nearly all malaria-related deaths (3). 
However, P. berghei is a unicellular parasite that infects 
rodent and is employed as a model organism in the 
laboratory for the experimental study of human malaria 
(4). 
The treatment of malaria with effective drugs 
remains a valuable method of reducing morbidity and 
mortality rate of the disease. Mostly used anti-malarial 
agents, such as chloroquine, amodaquine and 4-amino-
quinoline derivatives, inhibit the formation of ß-haema-
tin (malaria pigment), which is lethal to the parasite (5). 
Unfortunately, plasmodial parasites have deve-
loped resistance to most of these conventional drugs 
used in the treatment of malaria. Consequently, malaria 
resistance has led to an increase in the global cost of 
eradicating the disease, plus the financial implication of 
developing new drugs (6). The emergence and persistent 
problem of drug resistance, especially to P. falciparum, 
have directed the course of research towards the design 
of new and more potent drugs, natural or synthetic, with 
innovative approach as resurgence of interest in the old 
drugs (7). 
Following the discovery of cisplatin (a platinum-
containing anti-cancer drug), and its subsequent clinical 
success in the treatment of cancer, transition metal-based 
anti-malarial drugs came into existence. In the late 20th 
century, curiosity in complexes with increased therape-
utic potential started to arouse interests. Several studies 
have been conducted on complexation of some common 
anti-malarial drugs with metals (7). Some potentially 
efficacious metal-derivatized anti-malarial drugs are  
now in use (8). Many of the synthesized metal-based 
anti-malarial drugs were found effective in the reduction 
of malaria parasite better than the ordinary anti-malarial 
drugs.  
Previous works have shown that coordination 
with transition metal ions increases activities of some 
therapeutic agents (9). Developing appropriate, highly 
efficient and environmentally-friendly synthetic metallo-
drugs has become an emerging challenge. The global 
society is progressively aware of the environmental im-
pact of human activities as a result of the need to pro-
duce cleaner and more energy–efficient technologies 
(11). It has also been said that “the best solvent is no 
solvent” (12). Solventless synthesis has several benefits 
over solution synthesis. It is induced at room tempe-
rature instead of the refluxing temperature of 100-300 OC 
utilized in the solution synthesis. This method reduces 
environmental contamination by abolishing and mini-
mizing the use of organic solvents. Also, this method 
does not involve complex reaction and technique. The 
duration of synthesis is short (in the range of several 
minutes) compared to most solution-phase reactions 
(13). Therefore, in continuous search to find new anti-
malarial drugs that are effective against resistant strain 
of Plasmodium parasite, this paper present solvent-free 
mechanochemical synthesis of amodiaquine-zinc com-
plex as well as its characterization and anti-malarial effi-
cacy on P. berghei-infected mice and safety evaluations. 
MATERIALS AND METHODS 
Source of reagents 
Chemicals and reagents were of analytical grades 
and were used without further purification. Reagent and 
solvents were purchased from Sigma Chemical Co, St. 
Louis, MO, USA. Alkaline phosphatase (ALP), alanine 
aminotransferase (ALT), aspartate aminotransferase 
(AST) and lactate dehydrogenase (LDH) assay kits are 
products of Randox Laboratories Limited, Antrim, 
United Kingdom. 
FT-IR spectra of the ligand and the complexes 
were recorded in KBr pellets in the range of 4000-400cm-
1 on a SHIMADZU scientific model 500 FITR 
spectrophotometer with resolution 4(1/cm). Electronic 
spectra were done on an Aquamate Spectrophotometer, 
Model V4.60. X-ray powder diffraction patterns were 
recorded on a Huber Imaging Plate Guinier Camera 670 
with CuKα1-radiation. Typical scanning times were 20 
min over a 2θ-range of  0-40°. AAS analysis was carried 
out on an Atomic Absorption Spectrophotometer Model 
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6503 Jenway. Elemental analysis was performed on a 
Perkin-Elmer CHN Analyzer 2400 Series II.  
Source of mice and parasite 
Thirty (30) male albino mice (Mus musculus), 
average body weight 26.01 ± 0.21g were obtained from 
the Animal Breeding Unit of the Department of 
Biochemistry, University of Ilorin, Ilorin, Nigeria while 
the parasite P. berghei was obtained from the Institute of 
Advanced Medical Research and Training (IMRAT), 
University of Ibadan, Nigeria. 
Solid state synthesis of amodiaquine–zinc 
(AMDH+)2+  (ZnCl4)2-  complex 
Amodiaquine (2 mmol, 0.856 g) and zinc chloride 
(ZnCl2. 2H2O; 1 mmol, 0.136 g) were weighed into a 
previously washed and dried mortar. Using mortar and  
pestle at room temperature, the reactants were ground 
continuously for 15 min to a fine paste. The progress of 
the reaction was monitored by thin layer 
chromatography (TLC) at an interval of 5 min of 
grinding. The grinding continued for 30 minutes overall 
until no traces of reactants were found. The white 
powder obtained was washed with methanol to remove 
unreacted starting materials and dried at room 
temperature. Fine white powder was obtained as 
product. 
1a : Yield: 90.4 ; M. wt – 564.87 g/mol, M. pt – 264oC; 
Anal. Calc. for C 20H 24N 3 Cl 5OZn : C: 42.49; H: 4.25; N: 
7.44; Zn: 11.56. Found: C: 42.86; H: 4.20; N: 7.32, Zn:11.27. 
IR(KBR, cm-1): 3292,3095, 2974, 2336,1612,  1591, 1581, 
1508, 1435, 1366, 1263, 1257, 1190 , 1095, 1018, 920, 792, 
584, 484, 418;  UV-Vis(DMSO) ƛ,nm: 224, 296 
(AMDH)2+ = amodiaquine cation 
Scheme 1. Mechanochemical synthesis of tetrachlorometallate salts of amodiaquine 
Solvent-based synthesis of 
(AMDH)2+(ZnCl4 )2- 
A solution of amodiaquine (2 mmol, 0.856 g) in 
methanol (10 ml) was added to a solution of zinc 
chloride (ZnCl2.2H2O; 1 mmol, 0.240 g) in methanol (10 
ml). The resulting solution was refluxed for 120 min at 
70 oC, filtered and allowed to evaporate for 2 days at 
room temperature, after which white crystalline powder 
was obtained as product. 
1b : Yield: 78.4 M. wt = 564.87 g/mol, M. pt – 261oC, Anal. 
Calc. for C 20H 24N 3 Cl 5OZn : C:42.49; H: 4.25; N: 7.44; 
Zn: 11.56. Found: C:41.78; H: 4.14; N: 7.45, Zn: 11.30. 
IR(KBR, cm-1): 3296,3097, 2956, 2335,  1593, 1579, 1508, 
1437, 1363, 1265, 1255, 1195 , 1095, 1018, 922,  860.792, 
584, 480, 415;  UV-Vis(DMSO) ƛ,nm: 218, 279 
Anti-malarial screening and safety 
evaluation of amodiaquine-zinc complex 
Mice for experiment were infected as described by 
Sanchez-Delgado et al. (14). Swiss mice were randomly 
distributed into 6 groups of 5 mice each, as follows;  
Group 1  - Control; 
Group 2  - Parasite-infected but untreated (IBNT); 
Group 3  - Parasite-infected, chloroquine-treated (ITWC); 
Group 4  - Parasite-infected and amodiaquine-treated 
(ITWA); 
Group 5  - Parasite-infected and amodiaquine-Zn 
complex-treated (ITAZ); 
Group 6  - Not infected but amodiaquine-Zn complex-
treated (NIAZ). 
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The mice were inoculated intravenously with 0.2 
ml of 1 x 106 parasite-infected red blood cells suspended 
in buffered physiological saline (pH 7.4). Four days after 
infection, parasitemia levels of the mice were monitored 
everyday by counting parasites in blood smear fixed 
with 70% methanol and Giemsa stain. The slides were 
examined under the microscope at a magnification of 
×100. The level of parasitemia was thereafter determined 
by counting the number of infected erythrocytes / 1000 
erythrocytes in tail blood smears stained with Giemsa.  
0.2ml of each drug solution (corresponding to 7.7 mg/kg 
body weight) was daily and orally administered to the 
mice in each group from day 0 to day 3 of infection.  
Level of parasitemia was determined on day 4. 
The control animals were administered physiological 
saline solution only. The results obtained were presented 
as the percentage of infected cells or inhibition of 
parasites and percentage chemosuppression of parasite 
multiplication by the drugs. 
 Total number of  parasitized red blood cells counted x 100 
  % Parasitemia = 
  Total number of red blood cells counted 
 Parasitemia of test 
   % Chemosuppression = 100 –  (    )   x 100 
  Parasitemia of control 
Preparation of tissue and serum homogenate 
The experimental animals were sacrificed 24 h 
following the last day of drug administration by anaest-
hetizing with ether and blood samples were collected 
from the ocular orbit into heparinized bottles. They were 
then centrifuged and obtained from the plasma. The 
homogenates of the liver, kidney and small intestine 
were prepared in ice-cold 0.25 M sucrose solution to give 
a final volume of five times the original tissue weight 
(1.5 w/v). The homogenates were kept in well labeled 
container and stored in the freezer before use. 
Determination of enzyme activities 
Alkaline phosphatase (ALP) activity was 
determined according to the method described by 
Wright et al. (15). Aspartate and alanine aminotrans-
ferases (ALT and AST) activities were assayed using the  
method described by Reitman and Frankel (16). Lactate  
dehydrogenase (LDH) activity was determined using 
the method described by Wroblewski and La Due (17). 
Determination of haematological indices 
Hematological parameters analyzed include Hb, 
RBC, WBC, PVC, neutrophil and lymphocyte. The 
haematological parameters studied were determined 
using the automated haematology analyzer SYSMEX 
KX21 (SYSMEX Corporation, Japan). 
Statistical analysis 
Results were expressed as means of (5) five 
determinations ± SEM. Data were statistically analyzed  
using one-way ANOVA, followed by Student’s 
unpaired t-test. Differences were considered statistically 
significant at p < 0.05. 
Figure 1: Comparison of FT-IR spectra of (a) Amodiaquine ligand (b) [AMDH]2+ [ ZnCl4]2-
(Mechanochemically synthesized) (c) [AMDH]2+ [ ZnCl4]2- (solvent-based) 
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Table 1: Selected FT-IR absorption band (cm-1) for Amodiaquine 1a and 1b 
S/N Ligand/Complex ν(OH) νs(C=N) νs(C-H) ν(C-Cl) 
1. Amodiaquine 3408 1587 1587m, 1618s 1452b 
2. 
[AMDH]2+ [ZnCl4]2- 
Mechanochemical 1a 
3292 1594 
1587s, 
1616m 
1400b, 
1431b, 
1456w 
3. 
[AMDH]2+ [ZnCl4]2- 
Solvent-based 1b 
3296 1593 
1585s, 
1616m 
1400b, 
1431b, 
1456w 
RESULTS 
Compounds 1a and 1b were obtained as white 
powder via mechanochemical grinding and refluxing in 
methanol. The mechanochemical method was carried 
out by manual grinding of Amodiaquine and Zinc 
chloride dihydrate using mortar and pestle. The reaction 
was done within 30 minutes at room temperature as 
compared to solvent-based reaction (120 min in 
methanol at 70 OC) and 2 days for product to form. The 
elemental analysis and spectroscopic data (IR, UV-VIS 
spectra and PXRD) of the compounds prepared via the 
two different methods are almost identical.  The IR 
spectra of the compounds are shown in Figure 1 and 
selected bands are given in Table 1. Comparison of the 
spectra of Amodiaquine with 1a and 1b  showed that the 
band due to ν(OH) at 3408 cm-1 in the free amodiaquine 
ligand shifted to 3292 cm -1 in 1a and 3296 cm -1 in 1b as a 
result of  hydrogen bonding between this group and 
chlorine atoms and also of mechanical stirring and 
complex formation –  the band at  1587 cm-1 assigned to 
ν (C=N) experienced little shift to 1591 in  1a and 1593 
cm- 1 in 1b; however, this is not significant enough to 
indicate coordination. The spectroscopic data combined 
with elemental analysis results support the structures 
proposed for 1a and 1b (Scheme 1). 
IR studies 
The absorption band in range 2931- 2974 cm-1 due 
to ν(C-H) is attributed to stretching vibration of the  
methylene group in quinuclidine  molecule for the 
compounds 1a and 1b. 
The  ν(C-Cl)  in quinolone group of the 
Amodiaquine  observed at  1095 cm-1  did not change 
significantly in 1a and 1b, indicating that chlorine atom 
is not involved in the coordination to the metal ion. 
Results from FTIR data for these compounds 
revealed that there is no direct metal-drug coordination. 
In addition, the FT-IR spectra of the complexes synthe-
sized via the two methods are identical, but different 
from the free ligand (amodiaquine), suggesting that both 
methods produced similar products.  
Electronic spectra 
UV/VIS spectra data of Amodiaquine 1a and 1b   
are given in Table 2. It can be seen from the table that 
selected UV/VIS spectrum of the Amodiaquine presents 
two absorption bands at λmax = 210 nm and 256 nm 
assigned to π → π * and π →n*  . The same band are 
obtained around the same wavelengths, in 1a (224 nm 
and 296 nm in 1b (218 nm and 278 nm). As expected, 
Zn(II) compounds do not have additional bands in the 
visible region. Batochromic shifts of the first and second 
bands points to complex formation. It has d10  
configuration as there is no d-d transition. 
X-ray powder diffraction analysis 
Figure 2 shows that the powder x-ray diffraction 
patterns (PXRD) of the mechanochemical product (solid- 
state compound) was different from the PXRD of the 
reactants (amodiaquine ligand and Zn(II) ion. New 
peaks corresponding to the mechanochemical product 
were observed at 2θ = 16.30o, 17.60o, 22.60o and 22.25o 
which are absent in the ligand indicating formation of 
new phase.   Quantitative estimation of the 2θ PXRD 
patterns of the product 1a and 1b was carried out. The 
major peaks in PXRD pattern of 1a were observed at 2θ= 
6.10, 7.50, 11.00, 13.10, 15.30, 17.60, 19.65, 21.35, 22.60, 
25.25, 29.56, 32.40, while that of 1b were observed at 2θ= 
6.02, 7.53, 11.20, 12.95, 15.20, 17.50, 19.60, 21.30, 22.50, 
25.10, 29.60 and 32.40. The closeness of the 2θ shown in 
Figure 2 indicates that the two compounds 
mechanochemical product and solvent-based (products) 
are identical.  
In-vivo anti-malarial and safety evaluation 
Figure 3 represents the percentage of parasite-
amia in infected mice treated with chloroquine, amodia- 
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quine and amodiaquine-Zn complex. There was no 
significant increase (p > 0.05) in parasitemia in the mice 
that were infected and not treated when compared to 
parasite level on day 0. The parasite level in mice treated 
with chloroquine and amodiaquine-Zn complex redu-
ced below 5% by the 5th day, while those treated with 
amodiaquine decreased by 6%. The percentage redu-
ction of parasitemia in groups treated with chloroquine 
and amodiaquine-Zn complex showed no significant 
difference (p > 0.05). However, all the animals in all the 
test groups survived beyond the experimental period. 
Table 2: UV-Visible Spectra of Amodiaquine 1a and 1b 
Ligand/ compound Wavelength(nm) Assignments 
Amodiaquine 210 
256 
π→π* 
n→π*
1a 224 
296 
π→π* 
n→π* 
1b 218 
278 
π→π* 
n→π* 
Figure 2: Comparison of XRPD patterns of reactants - (a) ZnCl2 (b) Amodiaquine ligand 
(c) [AMDH]2+ [ ZnCl4]2-  (Solvent-based) (d) [AMDH]2+ [ ZnCl4]2-   (Solvent-free) 
Table 3: Percentage of chemosuppression of parasite multiplication by the drugs 
Treatments Day 5 Day 6 Day 7 
Chloroquine 35.28 65.00 92.85 
Amodiaquine 29.28 62.57 85.42 
Amodiaquine-Zn 32.85 63.57 90.85 
Table 3 represents the percentage of chemosup-
pression of parasite multiplication following admini-
stration of amodiaquine and amodiaquine-Zn complex. 
The percentage of chemosuppression of mice treated 
with amodiaquine-Zn complex is relatively similar to 
that of the chloroquine group which increased signi-
ficantly (p < 0.05). Amodiaquine attained 85.42% by day 
7, while amodiaquine-Zn complex attained 90.85%. 
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Tables 4-7 show the effect of the administration of 
amodiaquine, amodiaquine-zinc complex and chloro-
quine to mice (infected and uninfected) for four days on 
the activities of ALP, ALT, AST and LDH, respectively.  
There was a significant reduction (p < 0.05) in the activity 
of ALP, when compared with the control in liver, kidney 
and small intestine of the treatment groups. The 
reduction was well pronounced in the group treated 
with amodiaquine-zinc complex and accompanied by a 
significant increase (p < 0.05) in the enzyme activity in 
the plasma of all the treated groups (Table 4). The 
activity of ALT in all the studied organs of the treatment 
groups decreased, with a concomitant increase in the 
plasma enzyme activity (Table 5). The administration of 
amodiaquine-Zinc complex caused a significant 
decrease (p < 0.05) in the level of AST of the studied 
organs in both infected and non-infected animals, with a 
concurrent rise in the plasma AST activity. Similar 
pattern was observed in the other treatment groups that 
received chloroquine and amodiaquine, but this is less 
pronounced when compared to that of amodiaquine-
zinc complex (Table 6). Figure 3 represents the percent-
age of parasitaemia in infected mice administered amo-
diaquine and amodiaquine-zinc complex. LDH activity 
of the liver, kidney and small intestine (except the 
kidney of the non-infected group) decreased signi-
ficantly (p < 0.05), while there was a corresponding 
increase in the activity of the enzyme in the plasma 
when compared with the controls (Table 7). Table 8 
presents the effect of the administration of amodiaquine 
and amodiaquine-Zn complex on heamatological 
indices of infected and uninfected mice. There was a 
significant decrease (p < 0.05) in the levels of PCV, Hb, 
RBC and lymphocytes and a significant increase (p < 
0.05) in WBC and neutrophil concentrations across all 
the treatment groups when compared with control.  
Table 4: Effect of amodiaquine and amodiaquine-Zn complex on the specific activity of 
alkaline phosphatase (ALP) in selected tissues and plasma of mice 
Control IBNT ITWC ITWA ITAZ NIAZ 
Liver  2.58 ±  0.21a 1.31 ± 0.09b 1.12 ±0.08c 1.17 ±0.99c 1.09 ± 0.05c 1.11 ± 0.07c 
Kidney  3.30 ±  0.17a 3.09 ± 0.17a 1.98± 0.09b 2.00±0.19b 1.92±0.08b 1.99 ± 0.05b 
Small Intestine  4.31 ± 0.32 a 3.41 ± 0.22a 2.19 ±0.10b 2.37±0.21b 1.99±0.06b 2.01 ± 0.09b 
Plasma  1.75 ±  0.07a 2.50 ± 0.08b 3.44 ±0.11c 3.33 ±0.10c 4.31 ±0.21d 3.99 ± 0.13c,d 
Values are mean of 5 determinations ± SEM. Rows with different superscripts are significantly (p < 0.05) different. 
Key: 
IBNT -Infected but not treated 
ITWC-Infected and treated with chloroquine 
ITWA-Infected and treated with amodiaquine 
ITAZ-Infected and treated with amodiaquine-Zn  
NIAZ-Not infected but treated with amodiaquine-Zn  
Table 5: Effect of amodiaquine and amodiaquine-Zn complex on the activity of alanine 
aminotransferase (ALT) in selected tissue and plasma of mice 
Control IBNT ITWC ITWA ITAZ NIAZ 
Liver 15.50 ± 1.12a 9.75 ± 0.53 b 7.50 ± 0.17c 6.25 ± 0.24d 7.75 ± 0.16c,e 7.80 ± 0.25 e 
Kidney  1.63 ± 0.02a 0.93 ± 0.06b 0.60 ± 0.02c 0.32 ± 0.01d 0.37 ± 0.01d 0.32 ± 0.01d 
Small Intestine 1.87 ± 0.13a 0.94 ± 0.04b 0.64 ± 0.02c 0.32 ± 0.02d 0.19 ± 0.01e 0.13 ± 0.011e 
Plasma 1.83 ± 0.12 a 2.67 ± 0.14b 2.64 ± 0.11b 3.52 ± 0.10c 3.60 ± 0.14c 4.17 ± 0.23d 
Values are mean of 5 determinations ± SEM. Rows with different superscripts are significantly (p < 0.05) different. 
Key: 
IBNT -Infected but not treated 
ITWC-Infected and treated with chloroquine 
ITWA-Infected and treated with amodiaquine 
ITAZ-Infected and treated with amodiaquine-Zn  
NIAZ-Not infected but treated with amodiaquine-Zn  
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Table 6: Effect of amodiaquine and amodiaquine-Zn complex on the activity of aspartate  
aminotransferase (AST) in selected tissues and plasma of mice 
Control IBNT ITWC ITWA ITAZ NIAZ 
Liver  5.23± 0.14 a 3.89± 0.16b 2.50± 0.13c 2.75± 0.15c 2.01± 0.09d 2.11±    0.09d 
Kidney  1.86± 0.04a 1.07± 0.02b 0.63± 0.04c 0.56± 0.02c 0.23± 0.01d 0.23 ±   0.01d 
Small Intestine  0.83 ± 0.01a 0.46 ± 0.02b 0.14± 0.01c 0.16± 0.01c 0.12± 0.01c 0.13 ±   0.01c 
Plasma  1.41 ± 0.10a 2.05 ± 0.08b 2.16 ± 0.04b 2.54 ± 0.13c 2.57 ± 0.15c 2.60 ±   0.13c 
Values are mean of 5 determinations ± SEM. Rows with different superscripts are significantly (p < 0.05) different. 
Key: 
IBNT -Infected but not treated 
ITWC-Infected and treated with chloroquine 
ITWA-Infected and treated with amodiaquine 
ITAZ-Infected and treated with amodiaquine-Zn  
NIAZ-Not infected but treated with amodiaquine-Zn  
Values are means of 5 determinations ± SEM and Bars with different superscripts are significantly different at (p < 0.05). 
Figure 3: Percentage of parasitaemia of infected mice administered amodiaquine and amodiaquine-Zn complex 
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Table 7: Effect of amodiaquine and amodiaquine-Zn complex on the activity of lactate  
dehydrogenase (LDH) in selected tissues and plasma of mice 
Control IBNT ITWC ITWA ITAZ NIAZ 
Liver 6.84 ± 0.52a 4.29 ± 0.29b 3.83 ± 0.23c 3.24 ± 0.27c 3.86 ± 0.18c 3.94 ± 0.16c 
Kidney 9.42 ± 0.43a 6.89 ± 0.12b 3.57 ± 0.29c 3.87 ± 0.13c 6.16 ± 0.46d 10.15 ± 0.71e 
Small Intestine  4.45 ± 0.19a 1.83 ± 0.06b 1.54 ± 0.03b 1.8 2±0.01b 1.6 5± 0.02b 1.55 ± 0.04b 
Plasma LDH  1.19 ± 1.02a 0.61 ± 0.1b 042 ± 0.01c 0.39 ± 0.01c 0.28 ± 0.01d 0.22 ± 0.01d 
Values are mean of 5 determinations ± SEM. Rows with different superscripts are significantly (p < 0.05) different. 
Key: 
IBNT -Infected but not treated 
ITWC-Infected and treated with chloroquine 
ITWA-Infected and treated with amodiaquine 
ITAZ-Infected and treated with amodiaquine-Zn  
NIAZ-Not infected but treated with amodiaquine-Zn  
Table 8: Effect of amodiaquine and amodiaquine-Zn complex on mouse haematological indices 
Parameters Control IBNT ITWC ITWA ITAZ NIAZ 
PCV (%) 40.25 ± 1.88a 34.50 + 1.55b 30.11 ± 1.49c 30.25 ± 1.75c 31.33 ± 2.33c 32.75+1.25c 
Hb (g/dl) 13.27 ± 056a 11.15 + 0.34b 10.79 ± 0.62b 11.50 ± 0.45b 10.40 ± 0.90b 11.17+0.28b 
RBC(x 1012/L) 4.66 ± 0.27a 2.28 ± 0.08b 2.20 ± 0.02b 2.15 ± 0.02b 2.06 ± 0.07b 2.26+0.06b 
WBC(x109/L) 3.67 ± 0.50a 5.47 ± 0.22b 5.50 ± 0.21b 5.37 ± 0.14b,c 6.30 ± 0.75c 6.82+0.77c 
Neutrophil(%) 22.00 ± 1.68a 32.75 ± 3.00a 43.17 ± 2.34b 44.75 ± 4.69b 38.66 ± 5.17b 43.75+4.60b 
Lymphocytes(%) 78.00 ± 1.68a 67.25 ± 3.01b 56.11 ± 3.84b 55.25 ± 4.69b 60.33 ± 9.17b 56.25+4.60b 
Values are mean of 5 determinations ± SEM. Rows with different superscripts are significantly (p < 0.05) different. 
Key: 
IBNT -Infected but not treated 
ITWC-Infected and treated with chloroquine 
ITWA-Infected and treated with amodiaquine 
ITAZ-Infected and treated with amodiaquine-Zn  
NIAZ-Not infected but treated with amodiaquine-Zn  
DISCUSSION 
Solvent-free reactions have gained increasing 
interest in recent years. Due to the problem of 
environmental pollution linked with solvent disposal 
and shrinking energy resources, there is a need to 
develop benign synthetic reactions which are simple and 
exhibit high atom economy. Synthesis from solution 
introduces additional costs related to solvent and its 
environmental impact and is also subject to limitation. 
As a society we are increasingly aware of the 
environmental impact of human activity and as a result 
of the need to develop cleaner and more energy–efficient 
technologies (18). 
The outburst of malaria and drug-resistant strain 
of plasmodium have made malaria a leading killer 
disease in the world. The challenge of malaria-drug 
resistant led researchers in the direction of metal-based 
anti-malarial drugs. Many metal-complexes anti-
malarial drugs have been reported to possess anti-
malarial activity better than their parent compounds (7). 
In this study, zinc(II) complex with amodiaquine 
(AMDH+)2+ (ZnCl4)2- was synthesized via two methods: 
mechanochemical and solvent-based methods. The 
mechanochemical method involves safe and 
environmentally friendly synthetic reactions which are 
simple and exhibit high atom economy. This is needful 
as synthesis from solution introduces additional costs 
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related to solvent and its environmental impact as well 
as its limitation (19). 
The spectroscopic spectra of the complexes 
synthesized via two methods suggest that both methods 
produced similar products. Moreover, comparing the 
XRPD patterns of the reactant and the product further 
proved that mechanochemically synthesized and 
solvent-based (AMDH+)2+ (ZnCl4)2-   are  identical. 
The reduction in percentage of parasitaemia, as 
well as the increase in percentage of chemosuppression 
of parasite when compared with the control, was more 
pronounced in mice treated with chloroquine and Zn(II) 
complex with amodiaquine) (AMDH+)2+ (ZnCl4)2-  
complex. This suggests that amodiaquine–zinc complex 
exhibits a stronger anti-malarial effect compared to its 
parent compound. The observed effects may be 
attributed to the fact that (AMDH+)2+ (ZnCl4)2- complex 
was more permeative into parasitized erythrocytes than 
its amodiaquine ligand. This is similar to what was 
reported by Arise et al. (2) on the study of lumefantrine 
complexed with copper. (AMDH+)2+ (ZnCl4)2- may have 
exchanged its bound zinc for ferric ions making the iron 
to be unavailable for vital parasite functions, thus 
suggesting (AMDH+)2+ (ZnCl4)2- may have a better 
therapeutic activity against amodiaquine (20-21).   
The determination of the activities of various 
enzymes in tissues and body fluids plays a vital role in 
disease investigation and diagnosis (22). Measurement 
of enzyme activities can also be used to indicate tissue 
cellular damage caused by a chemical compound long 
before histological changes (23). Alkaline phosphatase is 
a marker enzyme for the plasma membrane and 
endoplasmic reticulum (24). It is usually used to assess 
the integrity of the plasma membrane (25). Results from 
this study suggest that the integrity of membrane 
systems of the rat tissues have been compromised by the 
administration of the drugs in all test groups since they 
exerted significant decrease on the activity of the 
enzyme. This is in agreement with recent studies that 
have reported that some antimalarial agents as well as 
their metal-complexed forms such as chloroquine (26), 
amodiaquine (27) and lumefantrine-copper complex (2) 
are capable of causing damage to the liver.  
The significant reduction of lactate 
dehydrogenase (LDH), an enzyme associated with the 
cytosol (28), in the studied tissues, and its concurrent 
increase in the plasma, also suggest damage to plasma 
membrane by the drugs leading to excessive leakage of 
cytosolic materials including LDH into extracellular 
fluids (29). 
The activity of alanine aminotransferase (ALT) in 
the blood increases when cells are damaged or dead (30). 
Increase in the activities of serum ALT and AST as 
observed in this study may be due to loss from some 
tissue into extracellular fluids because of the change in 
disruption of plasma membrane as stated earlier. High 
serum levels of AST and ALT have been used as 
markers for some forms of liver disorders. The 
significant fall in the levels in the liver, kidney and small 
intestine of ALT and AST activities in all the treatment 
groups is suggestive of damage to the plasma 
membrane of these tissues at the cellular level, leading to 
increased efflux of these enzymes into the extracellular 
fluid (29). While the decrease in the RBC and PCV 
observed in groups of mice infected and treated might 
be due to the decrease in the rate of production of 
erythrocytes, it may also suggest that that the drugs 
lacked erythropoeitin potential (30). The increase in 
WBC and neutrophil might be an indication that there 
was a challenge on the immune system. 
CONCLUSION 
In conclusion, mechanochemical synthesis of 
amodiaquine-zinc represents an ideal method of 
synthesizing a derivatized amodiaquine-zinc with no 
environmental pollution on the order of several minutes 
when compared to the solvent-based that leads to 
environmental pollution and takes a longer period of 
time. Coordination of zinc to amodiaquine by 
mechanical induction enhanced its antimalarial activity, 
while the alterations in the investigated biochemical 
parameters suggest selective, functional and structural 
toxicity. Thus, prolonged use of amodiaquine-zinc may 
not be completely safe for oral treatment. 
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Mehanohemijska sinteza i procena in vivo antimalarijske efikasnosti i 
bezbednosti amodiakin-cink kompleksa 
Rotimi Olusanya Arise1, Sunday-Nwaso Elizabeth1, Samuel Tobi Farohunbi1, 
Mikhail Olugbemiro Nafiu1, Adedibu Clement Tella2 
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SAŽETAK 
Do sada su razvijeni neki od antimalarijskih lekova na bazi metala. U ovoj studiji opisana je 
mehanohemijska sinteza, karakterizacija kompleksa Zn (II) sa amodiakinom, kao i njegova antimalarijska 
efikasnost na miševima zaraženim Plasmodium bergheimom i procena njegove bezbednosti. 
U studiji je procenjena mehanohemijska sinteza bez upotrebe rastvarača i karakterizacija kompleksa Zn 
(II) sa amodiakinom, kao i njegova antimalarijska efikasnost na NK-65 miševima inficiranim pomoću 
Plasmodium berghei. 
Derivatizacija amodiakina sa cink (II) jonom povećala je aktivnost leka kroz značajno poboljšanje (p < 0,05) 
supresije parazitemije kod potvrđene malarije u poređenju sa kontrolnom grupom, dok je njegov kapacitet za 
čišćenje parazita malarije bio sličan onome kod hlorokv .in aZapaženo je značajno smanjenje aktivnosti alkalne 
fosfataze, laktat dehidrogenaze, alanina i aspartat aminotransferaza u jetri, bubrezima i tankom crevu, dok su se 
njihovi nivoi značajno povećali u plazmi. Nivoi PCV, Hb, RBC i limfocita bili su značajno smanjeni (p < 0,05), a 
uočeno je i značajno povećanje (p < 0,05) koncentracija leukocita i neutrofila u svim grupama koje su lečene u 
poređenju sa kontrololnom grupom. 
Rezultat ukazuje da je koordinacija cinka (II) sa amodiakinom pomoću mehaničke indukcije poboljšala 
njegovu antimalarijsku aktivnost, dok su izmene u ispitivanim biohemijskim parametriama ukazivale na 
funkcionalnu i strukturnu toksičnost. Stoga, kompleks Zn (II) sa amodiakinom ne može biti potpuno bezbedan za 
produženu i ponovljenu upotrebu kao oralni antimalarijski lek. 
Ključne reči: antimalarijski, amodiakine-cink, mehanohemijska sinteza, in vivo i procena bezbednosti 
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